ETF Outlook for Week of March 3, 2014
Market Vectors Russia ETF (NYSE: RSX)
The Ukraine/Russia conflict heightened this weekend and some experts are predicting an all-out war over Crimea. On Monday morning the MICEX Index was lower by eight percent and the Russian Ruble was tumbling. The largest Russian ETF in the U.S. is RSX, which was already down 2.4 percent last Friday. Investors can expect massive selling for the ETF today on the open.
Best Low Price Stocks To Buy For 2015: Cancer Genetics Inc (CGIX)
Cancer Genetics, Inc. (CGI), incorporated on April 8, 1999, is an early-stage, diagnostic company. The Company focuses on developing and commercializing genomic tests and services to improve the diagnosis, prognosis and response to treatment (theranosis) of cancer. These cancers include hematological, urogenital and human papillomavirus (HPV)-associated cancers. It provides its tests and services to oncologists and pathologists at hospitals, cancer centers, and physician offices. In January 2012, the Company received CLIA approval for MatBA-SLL, its microarray for risk stratification in small lymphocytic lymphoma (SLL). In February 2013, the Company received CLIA approval for MatBA-DLBCL, its microarray for diagnosis, prognosis and patient monitoring in diffuse large B cell lymphoma (DLBCL). In addition, the Company is developing a series of other genomic tests in its core oncology markets. The Company develops and produces two types of deoxyribonucleic acid (DNA)-based genomic tests: microarrays and probes.
The Company is in the final stages of validating MatBATM-SLL for risk stratification in small lymphocytic lymphoma (SLL), a subset of CLL that presents as a mass, with Memorial Sloan-Kettering Cancer Center and Long Island Jewish / North Shore Hospital. The Company is also internally clinically validating the MatBATM microarray in a variety of additional lymphoma subtypes, including mantle-cell lymphoma (MCL), follicular lymphoma (FL), and diffuses large B cell lymphoma (DLBCL). Its MatBATM array has been designed to measure genetic markers at 80 specific genomic sites where genetic alterations are associated with mature B cell neoplasms.
CGI is also developing microarray tests for the diagnosis, prognosis and theranosis of a range of urogenital cancers. These include the UroGenRA microarray for kidney, prostate and bladder cancers and the UGenRA microarray for endometrial (lining of the uterus), ovarian and cervical cancers. UroGenRA detects genomic changes in over 100 r! egions of the human genome with potential diagnostic and/or prognostic value in one or more of these types of cancer. It has initiated clinical validation for UroGenRA targeting kidney and prostate cancers in collaboration with Memorial Sloan-Kettering Cancer Center. Its UGenRA microarray has been designed as a platform to detect genomic changes occurring in 83 regions of the human genome that have been linked to endometrial, ovarian and cervical cancers In addition, it develop and manufacture a portfolio of fluorescence in situ hybridization (FISH) based DNA probes focused on blood-based and solid cancers that it sell outside the United States. The Company laboratory services include: Oncology Testing Services, which are based on its microarray tests and are available only in its clinical laboratory; Esoteric Oncology Testing Services, which it offers a suite of esoteric oncology testing services for hematological, urogenital and HPV-associated cancers, and Clinical Trial Services, which also utilize its clinical laboratory to provide clinical trial services to biopharmaceutical companies and clinical research organizations.
Hematological Cancer Arrays: MatBA-CLL/SLL, Other Mat-BA and LeukA
MatBA is an oligonucleotide-based microarray the Company developed for the analysis of genomic alterations in mature B-cell neoplasms to determine prognosis and theranosis. MatBA incorporates a common architecture of specific genomic regions that can be applied across the seven major mature B-cell neoplasms. As a group, hematologic cancers (cancers of the blood, bone marrow or lymph nodes) display clinical, pathologic and genetic complexity. Importantly, the clinical course of the six main subtypes of these neoplasms ranges from indolent (follicular lymphoma) to aggressive (diffuse large B-cell lymphoma, mantle cell lymphoma and multiple myeloma), or mixed (chronic lymphocytic leukemia/small lymphocytic lymphoma, or CLL/SLL).
MatBA is designed to detect genomic copy number chan! ges in ma! ture B-cell neoplasms. The test relies on the comparative genomic hybridization of fluorescently differentially-labeled normal DNA and DNA extracted from the cancer specimen (array-CGH). Array-CGH utilizes minimal biopsy material and uses DNA as the analyte (the component whose properties are being measured). MatBA was custom-designed to represent 80 regions of the human genome which have diagnostic and/or prognostic value in one or more of the mature B-cell neoplasm subtypes as identified through our research and analysis efforts. Unlike other technologies such as FISH, array-CGH using MatBA simultaneously permits the detection of genomic gains and losses at multiple locations on a chromosome (loci) that characterize the mature B-cell neoplasm subtypes. For each subtype of B-cell neoplasm, cohorts of specimens with full clinical annotation are evaluated using MatBA to identify associations between single and weighted combinations of genomic gains/losses and clinically relevant endpoints.
The Company offers the application of MatBA for prognostication in one subtype of mature B-cell neoplasm, CLL, where about half of patients experience indolent disease, or slow progression, and the remaining half, a relatively aggressive progression. MatBA-CLL provides genetic-based information to guide clinical management of this disease. In January 2012, MatBA-SLL was approved under CLIA and accordingly may now be offered as an LDT by its laboratory. In January 2013, this assay received approval by CLIA and New-York State for clinical use, and accordingly may now be offered as an LDT by our reference laboratory.
During the year ended December 31, 2012, the Company had similar development of MatBA as a prognostic tool in two of the other main subtypes of mature B-cell lymphomas, namely DLBCL and FL. FL is characterized by a slow progression that in up to approximately 60% of cases transforms to DLBCL, an aggressive lymphoma. Prognostic and theranostic biomarkers of therapeutic options are req! uired for! these diseases.
Urogenital cancer arrays: UroGenRA, UGenRA
The UroGenRA microarray provides diagnostic and prognostic analysis for kidney, bladder and prostate cancer. Its initial launch, UroGenRA-Kidney targets kidney cancer. It also develops extensions of UroGenRA for bladder and prostate cancers. UGenRA provide diagnostic, prognostic and theranostic information for the primary gynecological cancers, cervical, ovarian and endometrial. UroGenRA is a CGH-based array which serves as a platform for the diagnosis, prognosis and theranosis of kidney, prostate and bladder cancers. It represents 101 regions of the human genome potentially with diagnostic, prognostic and/or theranostic value in one or more of these types of cancers. UroGenRA-Kidney For kidney cancer, UroGenRA is specifically designed to classify renal tumors into the four main subtypes (clear cell, papillary, chromophobe and oncocytoma), which is critical to patient management and treatment protocols.
UroGenRA-Prostate for prostate cancer, UroGenRA use prostate core/needle biopsy to assess genomic variability of the cancer and help in the identification of biomarkers for assessment of the risk of recurrence, to assess treatment options for intermediate risk patients, and to explore the genomic aberrations of circulating tumor cells. UroGenRA-Prostate is in the commercial development stage. UroGenRA-Bladder is a diagnosed bladder cancers are defined by the fact or extent of invasion of the muscle. UroGenRA-Bladder is in the clinical development stage.
UGenRA for Endometrial, Ovarian and Cervical Cancers
UGenRA is designed as a platform to detect gains and losses of genomic material in 83 regions of the chromosome associated with responses to particular therapies in patients with endometrial, ovarian and cervical. UGenRA-Endometrial Endometrial cancer is common cancer in women in the United States. In this disease, endometrial hyperplasia is a precursor lesion of endometr! ioid endo! metrial carcinoma (EEC). UGenRA Endometrial is in the clinical development stage.
UGenRA-Ovarian is cases of ovarian cancer. UGenRA Ovarian is in the clinical development stage. As of December 31, 2012, UGenRA-Cervical was approximately 11,270 cases of cervical cancer diagnosed and approximately 4,290 deaths from cervical cancer in the United States. UGenRA Cervical is in the clinical development stage.
Advisors' Opinion:- [By Lauren Pollock]
Biopharmaceutical development company CytRx Corp.(CYTR) and early-stage diagnostics company Cancer Genetics Inc.(CGIX) separately disclosed plans to sell stock. CytRx, whose offering of 10 million shares priced at an 18% discount, is aiming to raise money to fund its clinical trials, while Cancer Genetics wants to hire more sales and marketing personnel, as well as fund research and development. CytRx dropped, while Cancer Genetics fell.
- [By John Udovich]
Biotech and the cancer treatment segment of the biotech market has been a hot area for some time with important cancer stocks like large cap Celgene Corporation (NASDAQ: CELG) and small caps�Array BioPharma (NASDAQ: ARRY), Cancer Genetics Inc (NASDAQ: CGIX), EXACT Sciences Corporation (NASDAQ: EXAS) and�MetaStat Inc (OTCMKTS: MTST) all producing a steady flow of important news�for investors this week or in recent weeks. Consider the following:
- [By RedChip]
Cancer Genetics, Inc. (NASDAQ: CGIX) had a big run in September; at one point, shares were up more than 130% over their IPO and secondary offering price of $10.
- [By RedChip]
Cancer Genetics (NASDAQ: CGIX), an emerging leader in DNA-based cancer diagnostics, priced a $15 million secondary offering and began trading on the NASDAQ today.
The offering will bring in a sizable cash infusion to CGIX, setting the stage for continued expansion of the Company�� sales and marketing efforts, as well as further product development and commercialization. In addition, it will enable the Company to fund its joint venture investment with Mayo Clinic and retire mezzanine financing.
Best Japanese Companies To Buy Right Now: Glencore Xstrata PLC (GLCNF.PK)
Glencore Xstrata Plc is a diversified natural resource company. The Company operates in three segments: Metals and Minerals, which includes copper, nickel, zinc/lead, alloys, alumina/aluminum and iron ore; Energy Products, which includes controlled and non-controlled coal mining and oil production operations and investments in strategic handling, storage and freight equipment and facilities, and Agricultural Products, which focuses on grains, oils/oilseeds, cotton and sugar. The Company�� operations consist of over 150 mining and metallurgical sites, offshore oil production assets, farms and agricultural facilities. The Company is a producer and marketer of over 90 commodities, such as mobile phones, bicycles, cutlery, plastics and electricity. Effective January 2, 2014, Post Holdings Inc acquired Agricore United Holdings Inc from Viterra Inc, a unit of Glencore Xstrata PLC, and the transaction also included Dakota Growers Pasta Company, Inc. Advisors' Opinion:- [By Pendulum]
Century Aluminum was founded in 1995 as a part of Glencore (GLCNF.PK). In 1996, Century Aluminum became a public company. As of December 31, 2012:
"Glencore beneficially owned approximately 41.8% of our outstanding common stock and all of our outstanding Series A Convertible Preferred Stock. Through its ownership of common and preferred stock, Glencore has an overall 46.6% economic ownership of Century." (Source: Century Aluminum 2012 10-K)
Best Japanese Companies To Buy Right Now: Quanta Services Inc.(PWR)
Quanta Services, Inc. provides specialty contracting services primarily in North America. The company?s Electric Power Infrastructure Services segment designs, installs, upgrades, repairs, and maintains electric power transmission and distribution networks, and substation facilities; renewable energy generation facilities; and offers emergency restoration services, including repairing infrastructure to the electric power industry. Its Natural Gas and Pipeline Infrastructure Services segment designs, installs, repairs, and maintains natural gas and oil transmission and distribution systems, compressor and pump stations, and gas gathering systems, as well as offers related trenching, directional boring, and automatic welding services; and pipeline protection, integrity testing, rehabilitation and replacement, and fabrication of pipeline support systems, and related structures and facilities. This segment also provides airport fueling systems, and water and sewer infrastruct ure. It services customers engaged in the transportation of natural gas, oil, and other pipeline products. The company?s Telecommunications Infrastructure Services segment designs, installs, repairs, and maintains fiber optic, copper, and coaxial cable networks for video, data and voice transmission; and designs, installs, and upgrades wireless communications networks, including towers, switching systems, and backhaul links, as well as offers emergency restoration services. This segment serves customers in the wireline and wireless telecommunications, and cable television industries. Its Fiber Optic Licensing segment designs, procures, constructs, owns, and maintains fiber optic telecommunications infrastructure; and markets and licenses the right to use these point-to-point fiber optic telecommunications facilities. It provides its services to enterprise, education, carrier, financial services, and healthcare customers. The company was founded in 1997 and is headquartered in Houston, Texas.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Quanta Services (NYSE: PWR ) , whose recent revenue and earnings are plotted below. - [By Chad Tracy]
TransCanada is not the only company that stands to profit from the possible Keystone XL approval. Refiners such as Valero and LyondellBasell Industries (NYSE: LYB), as well as construction companies Deere & Co. (NYSE: DE) and Quanta Services (NYSE: PWR) all stand to gain if Keystone XL gets the green light.
Best Japanese Companies To Buy Right Now: Accretive Health Inc. (AH)
Accretive Health, Inc. provides revenue cycle management services for hospitals and healthcare providers in the United States. It offers integrated revenue cycle management services that help healthcare providers to manage their revenue cycles, which encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, bill preparation, and collections; quality and total cost of care services, which enable healthcare providers to manage the health of a defined patient population by identifying those individuals who are most likely to experience an adverse health event; and physician advisory services. Accretive Health, Inc. serves multi-hospital systems, including faith-based or community healthcare systems, academic medical centers, independent ambulatory clinics, and physician practice groups. The company was formerly known as Healthcare Services, Inc. and changed its name to Accretive Health, Inc. in August 2009. Accretive Healt h, Inc. was founded in 2003 and is headquartered in Chicago, Illinois.
Advisors' Opinion:- [By Jon C. Ogg]
Accretive Health Inc. (NYSE: AH) was downgraded to Neutral from Outperform at Credit Suisse.
Beam Inc. (NYSE: BEAM) was downgraded to Hold from Buy based on valuation at Argus.
- [By Jon C. Ogg]
Accretive Health Inc. (NYSE: AH) was downgraded to Perform from Outperform at Oppenheimer.
Alamos�Gold Inc. (NYSE: AGI) was reinstated as Buy with a target price of $21 in Canada, which would translate to closer to $20 in U.S. share prices (versus $16.33 current), at BofA/Merrill Lynch.
- [By Laura Brodbeck]
Wednesday
Earnings Expected From: Accretive Health, Inc (NYSE: AH), Monsanto Company (NYSE: MON), UniTek Global Services, Inc. (NASDAQ: UNTK) Economic Releases Expected: Eurozone interest rate decision and PPI data, US National Employment Report, British construction PMIThursday
Best Japanese Companies To Buy Right Now: j2 Global Inc (JCOM)
j2 Global, Inc., incorporated on December 14, 1995, is a provider of services delivered through the Internet. The Company provides cloud services to businesses of all sizes, from individuals to enterprises. The Company operates in two segments: Business Cloud Services and Digital Media. The Company's Digital Media business segment consists of the Web properties and business operations of Ziff Davis, Inc. (Ziff Davis). The Company�� cloud services and solutions include fax, voice and unified communications, email and customer relationship management, online backup, global network and operations, and customer support services. In February 2013, it acquired IGN Entertainment, Inc. On November 9, 2012, the Company acquired Ziff Davis. Effective March 18, 2013, it acquired MetroFax Inc. In April 2013, the Company acquired Backup Connect BV.
Business Cloud Services
The Company's eFax and MyFax online fax services enable users to receive faxes into their email inboxes and to send faxes via the Internet. eVoice and Onebox provides the Company's customers a virtual phone system with various available enhancements. The Company's FuseMail service provides the Company's customers email, archival and perimeter protection solutions, while Campaigner provides its customers email marketing solutions. KeepItSafe enables the Company's customers to securely backup their data and dispose of tape or other physical systems. The Company's CampaignerCRM business provides customer relationship management solutions designed to increase the Company's customers' sales and increase efficiency. The Company also generates Business Cloud Services revenues from patent licensing and sales and advertising. The Company�� Business Cloud Services and solutions are of two types: direct inward-dial number (DID) -based, which are services provided in whole or in part through a telephone number and non-DID-based, which are its other cloud services for business. As of December 31, 2012, the Company had DIDs issued! to approximately 2.1 million paying subscribers.
The Company's services allow individuals to receive and send faxes as email attachments. In addition to eFax , the Company offers online fax services under a variety of alternative brands, including MyFax , eFax Plus , eFax Pro, eFax Corporate and eFax Developer . eVoice is a virtual phone system that provides small and medium-sized businesses on-demand voice communications services, featuring a toll-free or local company DID, auto-attendant and menu tree. With these services, a subscriber can assign departmental and individual extensions that can connect to multiple United States or Canadian DIDs, including land-line and mobile phones and Internet protocol (IP) networks. These services also include advanced integrated voicemail for each extension, unifying mobile, office and other separate voicemail services and improving efficiency by delivering voicemails in both native audio format and as transcribed text. Onebox is a unified communications suite. It combines the features of many of the Company's other branded services, plus added functionality, to provide a virtual office. Onebox includes a virtual phone system, hosted email, online fax, audio conferencing and Web conferencing.
FuseMail offers hosted email, email encryption and email archival services to businesses. These solutions are hosted offsite and seamlessly integrated into a customer's existing email system. The services include hosted email, VirusSMART virus scanning, CypherSMART encryption services, SpamSMART SPAM filtering and VaultSMART / PolicySMART archiving, which delivers a secure, scalable email archiving and customizable compliance tool to correspond with a company's retention policy. Campaigner is an email marketing service that enables businesses to easily create and send personalized one-to-one email communications to subscribers and customers to build better relationships. Campaigner also helps businesses increase the size of their mailing lists, compl! y with em! ail regulations like CAN-SPAM and get more emails to more inboxes. CampaignerCRM is a cloud-based CRM solution specifically designed to help small/medium-sized businesses close more deals, reduce the sales cycle and sell larger deals. CampaignerCRM has a sales checklist capability that gives sales representatives a step-by-step plan to closing a deal. With CampaignerCRM's Social CRM capabilities, companies can seamlessly integrate a customer's latest information from Twitter, LinkedIn, and Facebook directly into their Contact profile. KeepItSafe provides managed and monitored online backup solutions for businesses, using its ISO-certified platform.
The Company's Business Cloud Services business operates multiple physical Points of Presence (POPs) worldwide, a central data center in Los Angeles and several remote disaster recovery facilities. The Company connects its POPs to its central data centers through redundant, and often times diverse, Virtual Private Networks (VPNs) using the Internet. The Company's network is designed to deliver value-added user applications, customer support and billing services for the Company's customers anywhere in the world and a local presence for its DID-based service customers from thousands of cities in 49 countries on six continents. The Company offers DIDs covering all major metropolitan areas in the United States, United Kingdom and Canada, and such other major cities as Berlin, Hong Kong, Madrid, Manila, Mexico City, Milan, Paris, Rome, Singapore, Sydney, Taipei, Tokyo and Zurich. The Company has customers located throughout the world.
The Company's Business Cloud Services customer service organization supports the Company's cloud services customers through a combination of online self-help, email communications, interactive chat sessions and telephone calls. The Company's Internet-based online self-help tools enable customers to resolve simple issues on their own, eliminating the need to speak or write to the Company's customer service re! presentat! ives. The Company's Business Cloud Services segment customer service organization provides email support seven days per week, 24 hours per day to all subscribers. Paying subscribers have access to live-operator telephone support seven days per week, 24 hours per day. Dedicated telephone support is provided for corporate customers 24 hours per day, seven days per week. Live sales and customer support services are available in nine languages, including English, Spanish, Dutch, German, French and Cantonese.
Digital Media
The Ziff Davis portfolio of Web properties, including PCMag.com, ExtremeTech.com, Geek.com, ComputerShopper.com, LogicBuy.com and Toolbox.com features reviews of technology products, technology-oriented news and commentary, professional networking tools for IT professionals and online deals and discounts for consumers. The Company generates Digital Media revenues from the sale of display advertising targeted to in-market technology buyers and from the sale of customer leads to online merchants and business-to-business leads to IT vendors. During the year ended December 31, 2012, Digital Media Web properties attracted 345 million visits and 1.1 billion page views.
PCMag is a trusted online resource for laboratory-based product reviews, technology news and buying guides. Toolbox.com is a network of online communities that allows experienced technology professionals to share collective knowledge and collaborate to resolve problems more efficiently. Toolbox.com includes professional networking tools, blogs, collaboration tools and reference guides. Geek.com is an online technology resource and community for technology enthusiasts and professionals. Its gaming site includes IGN.com and men's lifestyle site includes AskMen.com.
The Company competes with Google AdSense, DoubleClick Ad Exchange, AOL's Ad.com and Microsoft Media Network.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on j2 Global (Nasdaq: JCOM ) , whose recent revenue and earnings are plotted below. - [By Roberto Pedone]
Another potential earnings short-squeeze trade idea is cloud services player J2 Global (JCOM), which is set to release its numbers on Tuesday after the market close. Wall Street analysts, on average, expect J2 Global to report revenue $130.43 million on earnings of 71cents per share.
The current short interest as a percentage of the float for J2 Global is extremely high at 20.6%. That means that out of the 43.70 million shares in the tradable float, 9.01 million shares are sold short by the bears. If the bulls get the earnings news they're looking for, then shares of JCOM could easily explode higher post-earnings.
From a technical perspective, JCOM is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock has been uptrending strong for the last six months, with shares moving higher from its low of $38.07 to its recent high of $56.24 a share. During that uptrend, shares of JCOM have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of JCOM within range of triggering a major breakout trade post-earnings.
If you're in the bull camp on JCOM, then I would wait until after its report and look for long-biased trades if this stock manages to break out above its 52-week high at $56.42 a share (or Tuesday's intraday high if higher) on high volume. Look for volume on that move that hits near or above its three-month average action of 292,457 shares. If that breakout hits, then JCOM will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $65 to $75 a share.
I would simply avoid JCOM or look for short-biased trades if after earnings it fails to trigger that breakout, and then drops below some key near-term support levels at $54 to $53 a share with high volume. If we get that move, then JCOM will set up to re-test or possibly take out its ne
- [By Dave and Donald Moenning]
Internet Software & Services has been the place to be in 2013. In addition to Shutterstock (SSTK), just take a look at these constituents of this red-hot sub-industry: Pandora Media (P), Facebook (FB), j2 Global (JCOM), Yelp (YELP), CoStar Group (CSGP),LinkedIn (LNKD), etc. The list of superb stocks in the Internet Software & Services space goes on and on. Focusing on stocks in the top-performing sub-industries usually helps bullish trades, so today, let's take a closer look at Shutterstock Inc for a short-term long trade.
Best Japanese Companies To Buy Right Now: KLA-Tencor Corporation (KLAC)
KLA-Tencor Corporation engages in the design, manufacture, and marketing of process control and yield management solutions for the semiconductor and related nanoelectronics industries. It offers equipment comprising wafer and integrated circuit (IC) defect monitoring, review, and classification; reticle defect inspection and metrology; packaging and interconnect inspection; critical dimension metrology; pattern overlay metrology; film thickness, surface topography, and composition measurements; measurement of in-chamber process conditions, wafer shape, and stress metrology; computational lithography tools; and yield and fab-wide data management and analysis systems. The company also provides products that serve the high brightness light emitting diode, data storage, and photovoltaic industries, as well as general materials research. It primarily offers its products to wafer, IC, reticle, and disk manufacturers in the United States, Taiwan, Japan, Europe, Israel, Korea, and the Rest of Asia. The company was founded in 1975 and is headquartered in Milpitas, California.
Advisors' Opinion:- [By Sue Chang and Saumya Vaishampayan]
$KLAC: KLA-Tencor Corp. (KLAC) �shares rose 1.9%. Analysts at J.P. Morgan on Monday initiated coverage of KLA-Tencor and Lam Research Corp. (LRCX) �at overweight.
Best Japanese Companies To Buy Right Now: Varian Medical Systems Inc.(VAR)
Varian Medical Systems, Inc. designs, manufactures, sells, and services equipment and software products for treating cancer with radiotherapy, stereotactic radiotherapy, stereotactic body radiotherapy, stereotactic radiosurgery, and brachytherapy worldwide. Its Oncology Systems segment offers products, such as linear accelerators, brachytherapy afterloaders, treatment simulation and verification equipment, and accessories; and information management, treatment planning, and image processing software. This segment serves university research and community hospitals, private and governmental institutions, healthcare agencies, doctors? offices, and cancer care clinics. The company?s X-ray Products segment provides x-ray tubes for use in a range of applications, including computed tomography scanning, radiographic or fluoroscopic imaging, mammography, special procedures, and industrial applications; and flat panel digital image detectors for filmless x-ray imaging. It sells t hese products to imaging systems original equipment manufacturers that incorporate them into their medical diagnostic, dental, veterinary, and industrial imaging systems; independent service companies; and directly to end-users. The company also designs, manufactures, sells, and services Linatron x-ray accelerators, imaging processing software, and image detection products for security and inspection purposes, such as cargo screening at ports and borders, and nondestructive examination in various applications. In addition, it develops products and systems for delivering proton therapy; and technologies in the areas of digital X-ray imaging technology, volumetric and functional imaging, improved X-ray sources, and technology for security and cargo screening applications. The company was formerly known as Varian Associates, Inc. and changed its name to Varian Medical Systems, Inc. in April 1999. Varian Medical Systems, Inc. was founded in 1948 and is headquartered in Palo Alto , California.
Advisors' Opinion:- [By Ben Levisohn]
Varian Medical Systems (VAR) and Stryker (SYK) are heading in opposite directions after reporting very different earnings after the close today.
Getty ImagesShares of Stryker have gained 0.5% to $79–they were up as much as 3.1% at $81–after reporting a profit of $1.23, beating forecasts for $1.22, while revenue came in at $2.47 billion, ahead of forecasts for $2.43 billion. Stryker also said that its full year earnings would come in between $4.74 and $4.90 using new amortization rules. Because of that change it’s hard to tell how that compares to consensus estimates for $4.57.
Varian, meanwhile, has dropped 0.6% to $82 after it said it earned 91 cents a share, up 6% from a year ago and ahead of analyst forecasts for 90 cents, according to FactSet. Varian also predicted that full-year earnings would come in between $4.22 and $4.32 a share, straddling the consensus estimate of $4.29.
- [By Monica Gerson]
Varian Medical Systems (NYSE: VAR) is projected to post its Q4 earnings at $1.12 per share on revenue of $779.02 million.
Thermo Fisher Scientific (NYSE: TMO) is estimated to report its Q3 earnings at $1.28 per share on revenue of $3.18 billion.
- [By Seth Jayson]
Basic guidelines
In this series, I examine inventory using a simple rule of thumb: Inventory increases ought to roughly parallel revenue increases. If inventory bloats more quickly than sales grow, this might be a sign that expected sales haven't materialized. Is the current inventory situation at Varian Medical Systems (NYSE: VAR ) out of line? To figure that out, start by comparing the company's inventory growth to sales growth. How is Varian Medical Systems doing by this quick checkup? At first glance, not so great. Trailing-12-month revenue increased 7.2%, and inventory increased 13.0%. Comparing the latest quarter to the prior-year quarter, the story looks decent. Revenue grew 6.7%, and inventory increased 13.0%. Over the sequential quarterly period, the trend looks healthy. Revenue grew 13.3%, and inventory grew 0.6%. - [By WWW.GURUFOCUS.COM]
Varian Medical Systems (VAR) has been a staple in our portfolio since the fall of 2005. The stock has rebounded smartly, up +31% from its April 2013 lows through the first quarter. Varian continues to be the global market share and technological leader in the radiation oncology business. Unfortunately, the incidence of cancer continues its deadly growth. In the U.S. alone, the American Cancer Society projects that some 1.7 million people will be diagnosed with cancer. Expectations of new cancer cases around the world are approaching 25 million over the next three decades. Of these new cases, approximately two-颅��hirds will be treated with some sort of radiation therapy. Varian has been at the forefront of linear particle accelerator since the late 1940's. Today the Company's installed base numbers over 7,300 LINACS across the globe ��a 60% market share. As impressive as that may sound, the availability of state-颅��f-颅��he-颅��rt radiation therapy (radiosurgery and proton therapy) outside of the U.S. is woefully low. The developed world has access to 35 to 110 LINACS per million people over the age of 65. In the U.S., it's 110 LINACS per million. Western Europe and Japan is 35 to 65 per million. In India, Africa, Eastern Europe and Southeast Asia there are between 1 and 20 machines per million. In China there is less than 10 machines per million. Complementing the Company's long-颅��erm growth opportunity in radiation therapy is the secular trend in the "digitization of radiology," which is a key driver of their lucrative software and flat-颅��anel services business, plus their X-颅��ay tube replacement business that sells into the installed base of competing LINACS. The Company's initiatives to drive greater productivity continue to bear fruit. In 2013 sales per employee increased 14% and operating income per employee increased 20% over 2012 levels. Such productivity has helped the Company offset the continuing losses as they rollout their pro
No comments:
Post a Comment